{"id":"W4387810382","doi":"10.1016/j.annonc.2023.09.2727","title":"1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Shanghai Municipal Health Commission","keywords":"Medicine; Enzalutamide; Prostate cancer; Oncology; Biochemical recurrence; Internal medicine; Clinical endpoint; Cancer; Clinical trial; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001529863,0.0008783931,0.00120591,0.0004272523,0.0003440716,0.0009414558,0.000412928,0.0005448647,0.006940593],"category_scores_gemma":[0.00104346,0.0001435833,0.001530387,0.0004849914,0.0002797577,0.0006612933,0.0004158136,0.002114244,0.001115544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006660882,"about_ca_system_score_gemma":0.001050258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001182247,"about_ca_topic_score_gemma":0.00403136,"domain_scores_codex":[0.9995666,0.0001870287,0.00003144013,0.00005429466,0.00007011251,0.00009049814],"domain_scores_gemma":[0.9993778,0.0001614184,0.0001712024,0.00003803214,0.00008495523,0.0001665603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6831954,0.009608457,0.02385037,0.009869338,0.01079792,0.0004538019,0.0001799269,0.00701844,0.01219951,0.002099535,0.03494091,0.2057864],"study_design_scores_gemma":[0.2914428,0.3557001,0.1937938,0.00189525,0.02098915,0.002061733,0.0004557092,0.007595389,0.02379358,0.006350734,0.09566438,0.0002573831],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9146804,0.01568297,0.001900768,0.001059801,0.0005234639,0.003227426,0.02241036,0.0003046286,0.0402102],"genre_scores_gemma":[0.9600494,0.004370001,0.001544619,0.001003168,0.0003566961,0.003871377,0.01403398,0.00006548079,0.01470531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006940593,"threshold_uncertainty_score":0.02321863,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08273213936567804,"score_gpt":0.4181937329020148,"score_spread":0.3354615935363368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}